411 related articles for article (PubMed ID: 29678735)
1. Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.
Gao Y; Kraft JC; Yu D; Ho RJY
Eur J Pharm Biopharm; 2019 May; 138():75-91. PubMed ID: 29678735
[TBL] [Abstract][Full Text] [Related]
2. The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.
Halling Folkmar Andersen A; Tolstrup M
Viruses; 2020 Apr; 12(4):. PubMed ID: 32272815
[TBL] [Abstract][Full Text] [Related]
3. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
[TBL] [Abstract][Full Text] [Related]
4. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Sun J; Collier AC; Collins C; Shen DD; Ho RJY
J Control Release; 2018 Apr; 275():229-241. PubMed ID: 29432823
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
[TBL] [Abstract][Full Text] [Related]
7. Systems Approach to targeted and long-acting HIV/AIDS therapy.
Ho RJ; Yu J; Li B; Kraft JC; Freeling JP; Koehn J; Shao J
Drug Deliv Transl Res; 2015 Dec; 5(6):531-9. PubMed ID: 26315144
[TBL] [Abstract][Full Text] [Related]
8. Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.
Shao J; Kraft JC; Li B; Yu J; Freeling J; Koehn J; Ho RJ
Nanomedicine (Lond); 2016; 11(5):545-64. PubMed ID: 26892323
[TBL] [Abstract][Full Text] [Related]
9. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS; 2014 Nov; 28(17):2625-7. PubMed ID: 25102089
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based Pharmacokinetic Model Validated to Enable Predictions Of Multiple Drugs in a Long-acting Drug-combination Nano-Particles (DcNP): Confirmation with 3 HIV Drugs, Lopinavir, Ritonavir, and Tenofovir in DcNP Products.
Perazzolo S; Shen DD; Scott AM; Ho RJY
J Pharm Sci; 2024 Jun; 113(6):1653-1663. PubMed ID: 38382809
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
12. Integration of Computational and Experimental Approaches to Elucidate Mechanisms of First-Pass Lymphatic Drug Sequestration and Long-Acting Pharmacokinetics of the Injectable Triple-HIV Drug Combination TLC-ART 101.
Perazzolo S; Shireman LM; McConnachie LA; Koehn J; Kinman L; Lee W; Lane S; Collier AC; Shen DD; Ho RJY
J Pharm Sci; 2020 May; 109(5):1789-1801. PubMed ID: 32006525
[TBL] [Abstract][Full Text] [Related]
13. Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV).
Saravanan M; Asmalash T; Gebrekidan A; Gebreegziabiher D; Araya T; Hilekiros H; Barabadi H; Ramanathan K
Pharm Nanotechnol; 2018; 6(1):17-27. PubMed ID: 29424324
[TBL] [Abstract][Full Text] [Related]
14. Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges.
Labh R; Gupta R
Curr HIV Res; 2021; 19(1):4-13. PubMed ID: 32838720
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in drug targets and delivery of anti-HIV drugs.
Salama NN; Endsley A; Ho RJ
Infect Disord Drug Targets; 2006 Jun; 6(2):107-19. PubMed ID: 16789874
[TBL] [Abstract][Full Text] [Related]
16. [GESIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)].
Panel de expertos de GeSIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2015 Oct; 33(8):543.e1-43. PubMed ID: 25959461
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.
Roy U; Ding H; Pilakka-Kanthikeel S; Raymond AD; Atluri V; Yndart A; Kaftanovskaya EM; Batrakova E; Agudelo M; Nair M
Int J Nanomedicine; 2015; 10():5819-35. PubMed ID: 26425084
[TBL] [Abstract][Full Text] [Related]
18. Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates.
Koehn J; Iwamoto JF; Kraft JC; McConnachie LA; Collier AC; Ho RJY
AIDS; 2018 Nov; 32(17):2463-2467. PubMed ID: 30102655
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication.
Maeda K; Das D; Kobayakawa T; Tamamura H; Takeuchi H
Curr Top Med Chem; 2019; 19(18):1621-1649. PubMed ID: 31424371
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
Perazzolo S; Shen DD; Ho RJY
J Pharm Sci; 2022 Mar; 111(3):825-837. PubMed ID: 34673094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
